Boston Scientific (NYSE:BSX) Given New $129.00 Price Target at Truist Financial

Key Points

• Truist Financial has raised Boston Scientific's price target from $125.00 to $129.00, suggesting a potential upside of 37.24% from the stock's previous close.
• Boston Scientific reported $0.75 earnings per share for the last quarter, exceeding analysts' expectations of $0.72, with quarterly revenue reaching $5.06 billion.
• Insider selling has occurred, with executive executives selling over 124,000 shares, reflecting a significant decrease in their ownership stakes in the company.

Boston Scientific (NYSE:BSX - Get Free Report) had its price objective boosted by research analysts at Truist Financial from $125.00 to $129.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the medical equipment provider's stock. Truist Financial's price target would suggest a potential upside of 37.24% from the company's previous close.

Several other brokerages have also recently issued reports on BSX. Robert W. Baird lifted their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an "outperform" rating in a research note on Wednesday. Wells Fargo & Company upped their price target on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Royal Bank Of Canada reissued an "outperform" rating and set a $125.00 price objective on shares of Boston Scientific in a research note on Monday. Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Finally, Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $120.67.

Boston Scientific Price Performance

Shares of BSX stock traded down $3.63 during mid-day trading on Wednesday, hitting $94.00. 5,713,139 shares of the stock traded hands, compared to its average volume of 7,835,926. Boston Scientific has a twelve month low of $80.64 and a twelve month high of $109.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The company's 50-day simple moving average is $103.53 and its 200-day simple moving average is $102.13. The firm has a market cap of $139.28 billion, a price-to-earnings ratio of 55.91, a price-to-earnings-growth ratio of 2.34 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter last year, the business posted $0.62 earnings per share. The company's quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts expect that Boston Scientific will post 2.85 earnings per share for the current year.

Insider Transactions at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total transaction of $5,271,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,802,597.06. This represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 124,214 shares of company stock valued at $13,048,957. 0.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Boston Scientific

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FWL Investment Management LLC bought a new stake in shares of Boston Scientific in the 2nd quarter valued at about $26,000. Sound Income Strategies LLC grew its holdings in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 120 shares during the period. 1248 Management LLC bought a new stake in Boston Scientific in the first quarter valued at approximately $26,000. Y.D. More Investments Ltd acquired a new stake in Boston Scientific in the first quarter worth $27,000. Finally, Kilter Group LLC bought a new position in shares of Boston Scientific during the second quarter worth $30,000. Institutional investors own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.